INTANGIBLE ASSETS (Details) (USD $)	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Finite-Lived Intangible Assets [Line Items]
Accumulated Amortization	$ 355,000
Net	9,625,000	9,625,000	9,625,000
Cato Research discounted contract [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Life	3 years
Cost	355,000
Accumulated Amortization	355,000
Net
Patents for the AzoneTS-based product candidates and formulation [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Life	6 years
Accumulated Amortization
Net	1,305,000	1,305,000	1,305,000
Drug Master Files containing formulation, clinical and safety documentation used by the FDA [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Life	6 years
Accumulated Amortization
Net	1,500,000	1,500,000	1,500,000
In-process pharmaceutical products for 2 indications [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Life	6 years
Accumulated Amortization
Net	6,820,000	6,820,000	6,820,000
Technology related intangible assets [Member]
Finite-Lived Intangible Assets [Line Items]
Accumulated Amortization
Net	$ 9,625,000	$ 9,625,000	$ 9,625,000